Who is sponsoring NCT00356200?

NCT00356200 is sponsored by Tufts Medical Center.

What drugs are being tested in NCT00356200?

Interventions: Fluphenazine Decanoate, Placebo.

What is the status of NCT00356200?

NCT00356200 is currently TERMINATED.

Last reviewed 2010-12-20 · How we verify

Ascending-Dose, Double-Blind, Placebo-Controlled, Bilateral Study of Intralesional Fluphenazine Decanoate in Psoriasis

NCT00356200 Phase 2 TERMINATED Results posted

We are doing this research study to evaluate the effectiveness and safety of fluphenazine decanoate when injected with a needle into psoriasis lesions in adults. Fluphenazine decanoate is FDA (U.S. Food and Drug Administration) approved for use in people who have schizophrenia and psychotic symptoms. Fluphenazine decanoate is not approved by the FDA for use in psoriasis. Fluphenazine decanoate slows T cell growth in cells in laboratory test tubes. Its usefulness and safety in people with psoriasis will be investigated in this study.

Details

Lead sponsor	Tufts Medical Center
Phase	Phase 2
Status	TERMINATED
Enrolment	10
Start date	2006-07
Completion	2008-09

Conditions

Psoriasis

Interventions

Fluphenazine Decanoate
Placebo

Primary outcomes

Change in Target Lesion Score at Week 4 Compared to Baseline — Baseline to week 4
Change in score from 0-14 of target lesion disease activity based on scaling, erythema, and induration as determined by a physician assessor at week 4 compared to baseline (with 0 being no disease activity and 14 being maximum disease activity).

Countries

United States